Open AccessEfficacy and safety of bevacizumab in elderly patients with advanced colorectal cancer: A meta-analysis
Author(s) -
Xiuxing Chen,
Yanfeng Chen,
Xiuyu Cai,
Dongsheng Zhang,
Lei Fan,
Huijuan Qiu,
Bei Zhang,
Guifang Guo
Publication year - 2017
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_833_17
Subject(s) - medicine , bevacizumab , hazard ratio , odds ratio , confidence interval , randomized controlled trial , subgroup analysis , colorectal cancer , adverse effect , retrospective cohort study , meta analysis , gastroenterology , surgery , oncology , cancer , chemotherapy
Bevacizumab plus chemotherapy (CT) has been the standard treatment for advanced colorectal cancer (ACRC) in the last decade. However, whether geriatric patients treated with this combination achieved more benefits or suffered severer toxicities than CT alone remained controversial. This meta-analysis was aimed to provide more convincing evidence.